Call Us @ 0172 - 4680800 | info@indswift.com | NETWORKS | NSE - BSE
Researchers identify common genetic signature among three rare skin diseases
 
A group of researchers lead by a lecturer from the Universidad Carlos III de Madrid (UC3M), Marcela del Rio, from the CIEMAT, the Rare Diseases Networking Biomedical Research Centre (Initials in Spanish: CIBERER-- ISCIII) and Fundacion Jimenez Diaz has identified a common genetic signature among three rare skin diseases or genodermatoses: recessive dystrophic epidermolysis bullosa, Kindler syndrome and xeroderma pigmentosum. In the near future, these findings will allow efficient and safe evidence-based therapeutic approaches.

Through a global gene expression analysis (transcriptomic), the researchers were able to find and confirm a genetic signature common to these genodermatoses in patients' cells. The profile targets cellular activation and alteration of the dermal microenvironment (lower layer of the skin) which could favour the progression of the disease, as well as skin cancer.

Recessive dystrophic epidermolisis bullosa and the Kindler syndrome are diseases that cause fragility of the skin, caused by mutations in essential genes to attach the two layers of the skin. Patients with these diseases suffer from chronic erosion and wounds on the skin and mucosa, which causes terrible scarring and metastatic squamous cell carcinoma to develop. On the other hand, xeroderma pigmentosum is a disease characterised by high sensitivity to ultraviolet light, due to a deficiency in the DNA repair mechanisms, meaning patients are 110,000 times more likely to develop skin cancer.

This study, recently published in the British Journal of Dermatology, sheds light on the underlying molecular mechanisms of the diseases and presents new pharmacological targets that are useful for the treatment of associated effects. This possibility of treating patients therapeutically (for example, with drug repositioning) is a clinical priority in order to improve their quality of life.
News medical life.
 
Other Related News:
2019 FDA Approved Drugs
FDA announces another carcinogenic impurity in ARB blood pressure drugs
Researchers identify common genetic signature among three rare skin diseases
Health ministry to amend Section 71 of D&C Rules to make Pharm D professionals eligible to supervise drug manufacturing
3rd International Diabetes Summit to be held in Pune from March 8-10, 2019
Health ministry to roll out common IT platform for management of sales and manufacturing licenses of drugs
Cosmetics licences may come with product composition details to enhance safety; new clause proposed in Cosmetics Rules 2018
T-cell specificity found to play a role in attacks on myelin versus β-synuclein in MS
Plazomicin noninferior to meropenem for complicated UTI
New molecules reverse memory loss linked to depression, aging